| Progranulin (PGRN) | |
|---|---|
| Gene | [GRN](/genes/grn) |
| UniProt | P28799 |
| Protein Name | Progranulin |
| Molecular Weight | 63.5 kDa (full-length); secreted fragments: 6-25 kDa |
| Length | 593 amino acids |
| Localization | Secreted, Lysosomes, Cytoplasm |
| Expression | Neurons, Microglia, Macrophages, Epithelial cells |
| Associated Diseases | [Frontotemporal Dementia](/diseases/frontotemporal-dementia), [Amyotrophic Lateral Sclerosis](/diseases/als), [Alzheimer's Disease](/diseases/alzheimers-disease) |
Progranulin (PGRN) is a secreted glycoprotein encoded by the GRN gene that functions as a crucial regulator of neuronal survival, lysosomal function, immune response, and synaptic plasticity. The protein has a molecular weight of 63.5 kDa in its full-length form and is proteolytically processed into smaller granulins (6-25 kDa) that have distinct biological activities[1]. Progranulin is localized to multiple cellular compartments including the secretory pathway, lysosomes, and cytoplasm, where it participates in diverse cellular processes[2].
Haploinsufficiency caused by GRN mutations is one of the most common genetic causes of frontotemporal dementia (FTD), accounting for approximately 5-10% of all FTD cases and up to 20% of familial FTD[3]. Additionally, GRN mutations have been implicated in amyotrophic lateral sclerosis (ALS) and may modify Alzheimer's disease (AD) risk. The discovery that GRN mutations cause FTD through a haploinsufficiency mechanism, resulting in approximately 50% reduction in functional protein levels, has driven significant therapeutic development efforts focused on protein replacement or upregulation[4].
Progranulin is a 593-amino acid secreted glycoprotein with a molecular weight of 63.5 kDa. The protein contains multiple functional domains:
| Domain | Position | Description |
|---|---|---|
| Signal peptide | 1-18 | Directs secretion via secretory pathway |
| Granulin repeats | 19-564 | 7.5 tandem repeats of ~60-80 aa each |
| Cysteine-rich regions | Between repeats | Provide structural stability |
| N-glycosylation sites | Multiple | Affect secretion and stability |
The hallmark of progranulin is its series of granulin repeats:
Each granulin repeat contains:
Progranulin is cleaved by multiple proteases:
| Protease | Cleavage Site | Result |
|---|---|---|
| Elastase | Between repeats | Granulin fragments |
| Matrix metalloproteinases (MMP-3, MMP-9) | Variable | Multiple fragments |
| Cathepsin D | Within repeats | Smaller fragments |
| ADAMTS-4 | N-terminal | Truncated forms |
The cleavage products (granulins) have distinct biological activities:
Progranulin supports neuronal health through multiple mechanisms[5]:
Neurotrophic Activity:
Synaptic Function:
Anti-apoptotic Effects:
A critical function of PGRN is its role in lysosomal homeostasis[6]:
Lysosomal Enzyme Trafficking:
Autophagy Regulation:
Lipid Metabolism:
PGRN exerts immunomodulatory effects throughout the body[8]:
Inflammatory Response:
Microglial Function:
Wound Healing:
Most pathogenic GRN mutations lead to reduced protein levels through haploinsufficiency:
| Mutation Type | Mechanism |
|---|---|
| Nonsense mutations | Premature stop codons causing nonsense-mediated decay |
| Frameshift mutations | Insertions/deletions altering protein reading frame |
| Splice site mutations | Aberrant mRNA processing |
| Copy number deletions | Heterozygous deletions encompassing GRN |
The 50% reduction in PGRN levels is sufficient to cause FTD, demonstrating the critical importance of progranulin in neuronal maintenance.
Loss of functional PGRN leads to lysosomal impairment:
PGRN deficiency leads to TDP-43 (encoded by TARDBP) mislocalization:
PGRN deficiency promotes neuroinflammation:
GRN mutations cause TDP-43-positive FTD, representing one of the most common genetic forms:
| FTD Subtype | Percentage of GRN Cases |
|---|---|
| Behavioral variant FTD | ~60% |
| Primary progressive aphasia | ~25% |
| Corticobasal syndrome | ~15% |
Clinical Features:
Pathology:
Some GRN mutations cause ALS or ALS/FTD:
GRN may modify AD risk[2:1]:
Multiple approaches to restore PGRN levels[9]:
| Strategy | Approach | Status |
|---|---|---|
| Recombinant PGRN | Systemically administered protein | Preclinical |
| Gene therapy | AAV-mediated GRN delivery | Preclinical/early clinical |
| Small molecule inducers | Increase GRN expression | Discovery |
| Protein stabilization | Prevent PGRN degradation | Research |
Address lysosomal dysfunction in PGRN deficiency:
Target downstream pathology:
| Marker | Changes in GRN-FTD |
|---|---|
| Total tau | Elevated |
| Neurofilament light chain (NfL) | Markedly elevated |
| Cathepsin D activity | Reduced |
| PGRN | Reduced (~50%) |
Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006. ↩︎
Chintapaludi M, Baloh RH. Progranulin in the pathogenesis of Alzheimer's disease and related dementias. Neurobiology of Aging. 2021. ↩︎ ↩︎
Götzl JK, Capell A, Haass C. Understanding GRN-linked FTD. Trends in Neurosciences. 2020. ↩︎
Arrant AE, Roberson ED. Therapeutic strategies for progranulin-deficient FTD. Neuron. 2023. ↩︎ ↩︎
Eriksen JL, Mackenzie IR. Progranulin: a new player in neurobiology. Journal of Neurochemistry. 2007. ↩︎
Paushter DH, Du H, Feng T, Hu F. The lysosomal function of progranulin. Immunobiology. 2018. ↩︎
Evers BM, Rodriguez-Navas C, Tesla RJ, Pridgeon J, Sager RA, et al. Lipid alterations and lysosomal dysfunction in progranulin-deficient neurons. Nature Communications. 2023. ↩︎
Zhang Y, Chen X, Zong J. Progranulin: a key player in microglial function. Nature Reviews Neurology. 2019. ↩︎
Nguyen AD, Nguyen TA, Zhang J, Devireddy S, Zhou P, et al. A progranulin-derived therapeutic antibody restores synaptic function. Science Translational Medicine. 2021. ↩︎
Meeter LH, Dopper EG, Jiskoot LC, Sanchez-Valle R, Graff C, et al. Plasma and CSF progranulin in genetic FTD. Neurology. 2016. ↩︎
Ahmed Z, Sheng J, Xu ZF, Maxwell DK, Donnelly K, et al. Accelerated lipofuscino genesis and microglial activation in progranulin-deficient mice. Neurobiology of Aging. 2010. ↩︎